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RESULTS: The presence of diabetes-related co-morbidities,
notably neuropathy predicted overall TS and 3/5 domains (p <
0.05). Retinopathy impacted Device Satisfaction, age was related
to Lifestyle Flexibility (p < 0.05). No other baseline patient/
disease characteristic impacted TS. Lowered HbA1c impacted
overall TS, and 3/5 domains (p < 0.05). Number of hypoglycemic
events impacted Hypoglycemic Control, timing of the event was
related to overall TS and all domains (p < 0.001). Weight gain,
number of daily injections and treatment group did not impact
TS despite the presence of signiﬁcant treatment group difference.
When all signiﬁcant factors were examined together, HbA1c
reduction and neuropathy maintained their impacts on TS. The
impact of the number of hypoglycemic events remained only for
Hypoglycemic Control, while timing of the hypoglycemic event
impacted overall TS and 3/5 domains (p < 0.01). CONCLU-
SION: Contrary to clinical wisdom, the number of daily injec-
tions may not negatively impact TS when balanced by signiﬁcant
HbA1c treatment beneﬁts. Factors impacting TS when examined
independently did not always exert the same signiﬁcant inﬂuence
when assessed in combination with other factors. Clinicians
should judge the balance between positive and negative treat-
ment outcomes before considering treatment options.
ENDOCRINE DISORDERS
PEN1
DETERMINATION OF THE TOTAL COST OF DIAGNOSTIC
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OBJECTIVES: The prevalence of thyroid nodules is high with
four to seven percent in the general population. Fine-needle aspi-
ration cytology (FNA-t) is recommended as the reference test
because it is minimally invasive, presents an optimal positive pre-
dictive value and is cost-effective when compared to whole-body-
scan (WBS). The diagnosis is known for the fraction of patients
operated. Suspicious ﬁndings are a dilemma. For benign and
indeterminate results, a long-term follow-up delayed the time of
diagnosis. This study aims to determine the total cost of a true
diagnosis by FNA-t. The model takes account of false-positive,
false-negative, suspicious and indeterminate results.
METHODS: A Markov model was built describing the trajec-
tory and the management of patients, from the ﬁrst FNA-t and
until a conclusive diagnosis was obtained. We derived estimates
for patient, diagnostic accuracy values and follow-up from a ret-
rospective study, including patients who had their ﬁrst FNA-t in
2003 or 2004. Costs were computed from the viewpoint of the
hospital. A microcosting study was assessed to determine the unit
cost of FNA-t. Costs of hospital stays for surgery were extracted
from the hospital cost accounting. Sensitivity analyses were per-
formed. RESULTS: A total of 105/390 patients were operated.
Speciﬁcity and sensitivity values were respectively 86% and
78%. The unit cost of FNA-t was estimated to €118. Markov
modeling showed that the mean total cost of a true diagnosis
was €997 per patient, including unnecessary surgeries, FNA-t
and follow-up. Cost decreased with the capacity of the cytolo-
gist to minimize indeterminate results. CONCLUSION: The true
cost of a given procedure exceeds its unit cost of production.
This result is conditional to the performance of the cytologist
and is highly dependent on the 29% of indeterminate results.
Ultrasound-guidance would reduce this rate and the true cost by
a great deal at a relatively low unit cost.
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OBJECTIVE: To assess the economic impact to the US payer of
recombinant human growth hormone (rHGH) utilization in a
pediatric population. METHODS: rHGH may be administered
to pediatric patients via vial/syringe or pen injection systems pro-
vided by six manufacturers. Variation in annual drug cost is
largely a function of dosing efﬁciency and price per milligram
(mg). A budgetary impact model was developed to calculate drug
costs based on product waste and cost. Waste was calculated as
the difference between prescribed dose, based on patient weight,
and actual delivered dose, based on dosing increments and
maximum deliverable dose for pens and a ﬁxed percent waste as
derived from the literature for vials. Annual drug costs were cal-
culated based upon total mg delivered, using a daily dose of 0.03
mg/kg and wholesale acquisition cost. Total annual drug costs,
assuming equal use of vials and pens from each manufacturer,
were compared for two scenarios: 1) A mix based on national
market share and 2) restricting use to the product with lowest
waste. RESULTS: Based on the literature, waste for each vial
product was 23%, including injection error (15%) and
syringe/needle dead space (8%). Among individual pens, waste
was highest for Humatrope 24 mg (19.5%) and lowest for
Norditropin NordiFlex 5 mg (1.1%). Equal use of vials and pens
from each manufacturer resulted in the following product waste:
Tev-Tropin 23% (vial only), Nutropin 18.4%, Humatrope
14.5%, Genotropin 7.1%, Saizen 4.6%, and Norditropin 3.6%.
Restricting use to the product with least waste (Norditropin)
resulted in an 11.0% reduction in annual patient cost from
$19,196 to $17,089 compared to national share mix. CON-
CLUSION: Pen delivery systems result in less waste than vial and
syringe. Considering all approved delivery systems, Norditropin
resulted in the least product waste and lower annual patient cost.
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OBJECTIVE: To assess the economic impact to the US payer of
recombinant human growth hormone (rHGH) utilization in an
adult population. METHODS: rHGH may be administered to
adults via vial/syringe or pen injection systems provided by six
manufacturers. Variation in annual drug cost is largely a func-
tion of dosing efﬁciency and price per milligram (mg). A bud-
getary impact model was developed to calculate drug costs based
on product waste and cost. Waste was calculated as the differ-
ence between prescribed dose, based on patient weight, and
actual delivered dose, based on dosing increments and maximum
deliverable dose for pens and a ﬁxed percent waste as derived
from the literature for vials. Annual drug costs were calculated
based upon total mg delivered, using a daily dose of 0.016 mg/kg
and wholesale acquisition cost. Total annual drug costs, assum-
ing equal use of vials and pens from each manufacturer, were
compared for two scenarios: 1) A mix based on national market
share and 2) restricting use to the product with lowest waste.
